As described above, LCN2 and other proinflammatory and chemotactic factors were regulated by adalimumab treatment; therefore, we sought to ascertain, using the Spearman correlation test, whether LCN2 is related to those markers in RA patients. The gene discussed is LCN2; the disease is rheumatoid arthritis.